[
  {
    "ts": "2026-01-29T12:30:02+00:00",
    "headline": "These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?",
    "summary": "Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.",
    "url": "https://www.barchart.com/story/news/37294147/these-are-the-3-top-oversold-s-p-500-stocks-should-you-buy-the-dip",
    "source": "Barchart",
    "provider": "yfinance",
    "raw": {
      "id": "a4975bd7-7563-389b-b02c-9ea0764ceac7",
      "content": {
        "id": "a4975bd7-7563-389b-b02c-9ea0764ceac7",
        "contentType": "STORY",
        "title": "These Are the 3 Top Oversold S&P 500 Stocks. Should You Buy the Dip?",
        "description": "",
        "summary": "Abbott, Roper, and Humana are three blue-chip oversold stocks with significant upside potential for shareholders in January 2026.",
        "pubDate": "2026-01-29T12:30:02Z",
        "displayTime": "2026-01-29T12:30:02Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/barchart_com_477/04c571f09d4734b057e8abd1b79743b4",
          "originalWidth": 1600,
          "originalHeight": 1067,
          "caption": "Buy Sell cards by Kelly Sikkema via Unsplash",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LLDb2nwbJAUwuKCsnK_PCw--~B/aD0xMDY3O3c9MTYwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/barchart_com_477/04c571f09d4734b057e8abd1b79743b4.cf.webp",
              "width": 1600,
              "height": 1067,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/J3_VkzxylaJju0yLsomckg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/barchart_com_477/04c571f09d4734b057e8abd1b79743b4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barchart",
          "url": "https://www.barchart.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barchart.com/story/news/37294147/these-are-the-3-top-oversold-s-p-500-stocks-should-you-buy-the-dip",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/3-top-oversold-p-500-123002277.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "^GSPC"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "HUM"
            },
            {
              "symbol": "ROP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T05:33:44+00:00",
    "headline": "5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call",
    "summary": "Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this underperformance to price-driven volume declines, particularly following the loss of a major U.S. WIC contract and ongoing consumer price sensitivity. CEO Robert Ford acknowledged the need for a shift, stating, “This path is not sustainable long-term, so we began to make changes in the fourth quarter.” The com",
    "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-abbott-053344962.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "b3081e26-f98b-3881-a9b4-5fac9fe5336c",
      "content": {
        "id": "b3081e26-f98b-3881-a9b4-5fac9fe5336c",
        "contentType": "STORY",
        "title": "5 Insightful Analyst Questions From Abbott Laboratories’s Q4 Earnings Call",
        "description": "",
        "summary": "Abbott Laboratories ended the fourth quarter with sales growth below Wall Street’s expectations, driven primarily by ongoing challenges in its nutrition segment. Management attributed this underperformance to price-driven volume declines, particularly following the loss of a major U.S. WIC contract and ongoing consumer price sensitivity. CEO Robert Ford acknowledged the need for a shift, stating, “This path is not sustainable long-term, so we began to make changes in the fourth quarter.” The com",
        "pubDate": "2026-01-29T05:33:44Z",
        "displayTime": "2026-01-29T05:33:44Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/50dacd45543fdfb173bee15ba0da4c95",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ABT Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/kbpelHm2loJ7pwtgnrVvNw--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/50dacd45543fdfb173bee15ba0da4c95.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_TGsH1VQUVpMOlMxL72Mnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/50dacd45543fdfb173bee15ba0da4c95.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-abbott-053344962.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/5-insightful-analyst-questions-abbott-053344962.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T22:19:00+00:00",
    "headline": "Top Analyst Reports for Applied Materials, Linde & Abbott",
    "summary": "AMAT rides a semiconductor rebound as systems, services and ICAPS drive gains, even as China export curbs, memory lag and costs cloud near-term growth.",
    "url": "https://finance.yahoo.com/news/top-analyst-reports-applied-materials-221900110.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "10c75d89-ad8b-38f7-930f-0f00f02cffd3",
      "content": {
        "id": "10c75d89-ad8b-38f7-930f-0f00f02cffd3",
        "contentType": "STORY",
        "title": "Top Analyst Reports for Applied Materials, Linde & Abbott",
        "description": "",
        "summary": "AMAT rides a semiconductor rebound as systems, services and ICAPS drive gains, even as China export curbs, memory lag and costs cloud near-term growth.",
        "pubDate": "2026-01-29T22:19:00Z",
        "displayTime": "2026-01-29T22:19:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55",
          "originalWidth": 620,
          "originalHeight": 413,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7qxsqrZM8ueKEZZaMBimmA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55.cf.webp",
              "width": 620,
              "height": 413,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/z_Y9s.nod8y.0SuZhzp3mg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/045ba7ae9e660e2a91686804eef7ab55.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/top-analyst-reports-applied-materials-221900110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/top-analyst-reports-applied-materials-221900110.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AMAT"
            },
            {
              "symbol": "VALE"
            },
            {
              "symbol": "ABT"
            },
            {
              "symbol": "BDL"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2026-01-29T03:32:37+00:00",
    "headline": "Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
    "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.",
    "url": "https://finance.yahoo.com/news/q3-earnings-highs-lows-abbvie-033237142.html",
    "source": "StockStory",
    "provider": "yfinance",
    "raw": {
      "id": "ca1870bd-6f38-34b4-8ce1-c4b354269ee6",
      "content": {
        "id": "ca1870bd-6f38-34b4-8ce1-c4b354269ee6",
        "contentType": "STORY",
        "title": "Q3 Earnings Highs And Lows: AbbVie (NYSE:ABBV) Vs The Rest Of The Therapeutics Stocks",
        "description": "",
        "summary": "As the Q3 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the therapeutics industry, including AbbVie (NYSE:ABBV) and its peers.",
        "pubDate": "2026-01-29T03:32:37Z",
        "displayTime": "2026-01-29T03:32:37Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8",
          "originalWidth": 1400,
          "originalHeight": 700,
          "caption": "ABBV Cover Image",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K222hrzb0FJJlqrDZzsz7w--~B/aD03MDA7dz0xNDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 1400,
              "height": 700,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cD3IChyAhZhexmnMXW7jMA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/stockstory_922/621a415265c388bc8e9eb8ecaf0fb0a8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "StockStory",
          "url": "https://stockstory.org/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/q3-earnings-highs-lows-abbvie-033237142.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/q3-earnings-highs-lows-abbvie-033237142.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "ABT"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]